

## Special Issue

# Biology of Fibroblasts and Fibrosis

### Message from the Guest Editors

Fibroblasts are known to play a pivotal role in fibrosis, scarring and cancer progression. Understanding the distinct phenotypes of fibroblasts has become of great research interest since the introduction of high-level molecular techniques, including single-cell RNA and ATAC sequencing. As fibroblasts have been shown to play one of the most important roles in establishing fibrosis, understanding their biology is of utmost importance in developing therapies to potentially overcome this disease. We welcome papers that examine the role of fibroblasts in all aspects of their biology:

Topics can include (but are not limited to):

- Fibroblast heterogeneity;
- Fibroblast-associated organ fibrosis (liver, lung, skin, heart, and bowel);
- The role of fibroblasts in stromal cancer interactions;
- The role of fibroblasts in wound healing and inflammation;
- Emerging molecular techniques to characterize fibroblasts.

---

### Guest Editors

Dr. Michelle Griffin

Prof. Dr. Derrick Wan

Prof. Dr. Michael T. Longaker

---

### Deadline for manuscript submissions

closed (31 December 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/159010](https://mdpi.com/si/159010)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).